To treat anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other anaplastic lymphoma kinase inhibitor for metastatic disease.
To treat anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer whose disease has progressed on alactinib as the first anaplastic lymphoma kinase inhibitor therapy for metastatic disease.
To treat anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer whose disease has progressed on ceritinib as the first anaplastic lymphoma kinase inhibitor therapy for metastatic disease.
